Computed tomography-guided percutaneous biopsy for retroperitoneal lesions: a systematic review and meta-analysis.

The aim of this study is to perform a systematic review and meta-analysis of published studies to evaluate the efficacy and safety of computed tomography (CT)-guided percutaneous biopsy for retroperitoneal lesions. PubMed and the Cochrane Library were searched for English-language articles published up to October 2021 and reporting findings about patients with retroperitoneal lesions who underwent CT-guided percutaneous biopsy. The outcome measures assessed in this systematic review and meta-analysis are accuracy, false negative rate, and rate of minor and major complications. Heterogeneity among studies was evaluated by testing Cochran's Q and the inconsistency index statistics. Seven studies published from 1975 to 2021 were selected for the analysis of accuracy, false negative rates, and rate of major and minor complications. The pooled accuracy of CT-guided percutaneous biopsy for retroperitoneal lesions was 93.6% [95% confidence interval (CI), 88.1-96.6%], with high heterogeneity. The pooled false negative rate was 6.3% (95% CI, 3.3-11.7%) with high heterogeneity. Pooled rates of minor and major complications were 3.7% (95% CI, 1.6-8.6%) with moderate heterogeneity and 0.7% (95% CI, 0.4-1.1%) with low heterogeneity, respectively. CT-guided percutaneous biopsy for retroperitoneal lesions has been reported to have high accuracy with a limited rate of major complications.